Psychiatric assessment prior to and after switch from levetiracetam to brivaracetam: a questionnaire study
- Conditions
- Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizuresGeneralized idiopathic epilepsy and epileptic syndromesG40.2G40.3
- Registration Number
- DRKS00022128
- Lead Sponsor
- Epilepsiezentrum Kork
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
1. Participants with minimum age of 18 years and a diagnosis of epilepsy according to the 1989 International League Against Epilepsy (ILAE) classification
2. Participants receiving levetiracetam with an unchanged dose within 4 weeks.
3. The decision to switch from levetiracetam to brivaracetam will be made by the physician before and irrespective of his/her decision to include the participant in the study
1. Participants with known psychogenic non-epileptic seizures
2. Participants had already received brivaracetam in the past
3. Participants with a medical or a psychiatric condition that, in the opinion of the Investigator, could jeopardize or compromise the patient’s own ability to participate in the study: for example patients with status epilepticus, acute psychosis, acute respiratory distress, or participants with significant cognitive disorders etc.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The aim of this study is to investigate a psychiatric change in epilepsy patients switching from levetiracetam to brivaracetam using the following parameters (Questionnaires): SCL-90-S, BDI II, AEP and Qolie31-P, between June 2020 and June 2021. Participants in the study will fill the questionnaires prior to and 8 days after switching to brivaracetam. <br><br>
- Secondary Outcome Measures
Name Time Method